Research · Sep 3, 2026
Pfizer FY2025 revenue ~$63B (+5-8% YoY recovery from FY2023 trough $58.5B) with adj. operating margin recovering to ~30%. Post-COVID stabilization: Comirnaty COVID vaccine wound down from $37.8B FY2022 peak to ~$2B FY2025; Paxlovid declining toward ~$2-3B. Seagen $43B Dec 2023 acquisition adds ADC oncology franchise (ADCetris/Padcev/Tukysa/Tivdak — combined ~$5B FY2025 revenue, growing toward $7-9B by FY2027). Loss of exclusivity cliff: Eliquis 2026 (Pfizer share ~$7-8B), Ibrance 2027 (~$4B), Xtandi 2027 (~$1.5B) = $13-14B cumulative LOE exposure FY2026-FY2028. FY2026 thesis: Seagen oncology scaling + post-LOE pipeline launches + $4.5B cost program execution; key risks: LOE cliff exceeds pipeline replacement, ADC competitive intensity (Daiichi/AstraZeneca, Lilly, Merck ADC programs).
Research · Sep 3, 2026
BridgeBio Pharma Inc. (NASDAQ: BBIO) FY2025 revenue ~$425-510M (+250-330%) with adj. EPS ~-$2.50 to -$1.75 reflecting selected post-November 2024 ~$430M aggregate Attruby (acoramidis) approval (selected primary novel ATTR-CM transthyretin amyloid cardiomyopathy treatment) + selected continued post-2024 ~$140M+ aggregate Q1 2026 net product revenue trajectory + selected continued post-2024 ~$1.0B+ aggregate FY2026 Attruby revenue expectation under continued Founder + CEO Neil Kumar since 2015 (~10-year tenure as BridgeBio Pharma Founder + CEO). One of the world's leading clinical-stage biotechnology companies focused on genetic diseases + selected various rare diseases drug development. Founded 2015 as BridgeBio Pharma in Palo Alto California by Neil Kumar + selected various Third Rock Ventures partners + selected various Stanford University researchers (~10-year heritage); selected post-2015-2019 ~$1B+ aggregate venture capital funding; selected post-June 2019 NASDAQ listing IPO (~$348M aggregate raised); selected post-November 2024 ~$430M aggregate Attruby FDA approval for ATTR-CM. Headquartered in Palo Alto California; ~700+ employees globally with ~$425-510M revenue. Two primary product + clinical segments: Attruby (acoramidis) Commercial (~85%+ ~$365-435M), Pipeline + Clinical (~15% ~$60-75M). Geographic mix: US ~95%+ + International ~5%. Attruby + ATTR-CM cardiology launch: post-November 2024 ~$430M aggregate Attruby FDA approval; selected continued post-2024 ~$140M+ aggregate Q1 2026 net product revenue + ~$1.0B+ aggregate FY2026 revenue expectation; selected primary US ATTR-CM treatment + selected various Pfizer Vyndaqel + Vyndamax + Alnylam Amvuttra competitive positioning. Pipeline + clinical development: BBO-11273 + BBO-10203 + RAS oncology + achondroplasia + encaleret hypoparathyroidism + ADH1 + selected various early-stage pipeline. Founder + CEO Neil Kumar since 2015 (~10-year tenure); CFO Brian Stephenson. Capital + cash position + GAAP profitability: ~$1.2B+ aggregate cash + investments balance; ~$200-300M aggregate net debt position; selected post-2024 ~$300M aggregate convertible debt + ~$300M+ aggregate royalty financing; selected pathway to GAAP profitability inflection FY2026-2027 driven by Attruby launch. FY2026 thesis: Attruby + ATTR-CM cardiology launch + Pipeline + clinical development + ~$1.0B+ aggregate FY2026 Attruby revenue expectation + ~$1.0-1.2B aggregate cash + investments balance + selected pathway to GAAP profitability inflection FY2026-2027 + selected potential post-2024 capital return optionality. Risks: Attruby commercialization sustainability, Pfizer Vyndaqel + Vyndamax + Alnylam Amvuttra competition, GAAP profitability inflection trajectory, clinical pipeline risk, US payer + international reimbursement risk.
Research · Jun 9, 2026
Biotech M&A 2026 on track for best year since 2018. Patent cliffs (Keytruda 2028, Trulicity 2027) drive LLY/MRK/PFE acquisition urgency.
Research · Apr 28, 2026
Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.
Research · Apr 13, 2026
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
Research · Apr 13, 2026
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
Research · Apr 10, 2026
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
Research · Apr 10, 2026
CVS Health's recent settlement with the FTC over insulin pricing marks a pivotal moment in the pharmaceutical landscape. This article analyzes the potential winners and losers among pharmacies and drugmakers as regulatory scrutiny intensifies, highlighting key players like Eli Lilly, Novo Nordisk, and Walgreens Boots Alliance.
Research · Apr 9, 2026
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.
